GLP-1 (9-36) amide: Human GLP-1 Receptor Antagonist for Metabolic and Diabetes Research

Executive Summary: GLP-1 (9-36) amide is a peptide antagonist targeting the human GLP-1 receptor, with 100% purity confirmed by HPLC and mass spectrometry (APExBIO B5404). It is insoluble in water, DMSO, and ethanol, requiring specialized handling and immediate use after reconstitution. The peptide is pivotal for research in GLP-1 receptor signaling, metabolic regulation, and type 2 diabetes due to its ability to block GLP-1-induced cAMP responses (Chepurny et al., 2019). Quality control includes a Certificate of Analysis and Material Safety Data Sheet. The product facilitates reproducible interrogation of GLP-1 pathways, with verified selectivity in high-throughput FRET assays (link).

Biological Rationale

GLP-1 (9-36) amide is a truncated form of the incretin hormone GLP-1, generated by dipeptidyl peptidase-4 (DPP-4) cleavage of active GLP-1 (7-36) amide (Chepurny et al., 2019). The GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor expressed on pancreatic β-cells, neurons, and other tissues. GLP-1R activation stimulates cAMP production, potentiating glucose-dependent insulin secretion and lowering blood glucose. Antagonists like GLP-1 (9-36) amide are critical tools for dissecting the contributions of GLP-1 signaling in metabolic regulation, as they enable selective blockade of the receptor without confounding agonist activity. This approach is essential in differentiating the roles of GLP-1, glucagon, and related peptides within metabolic and diabetes research (related review).

Mechanism of Action of GLP-1 (9-36) amide

GLP-1 (9-36) amide exerts its effects by binding competitively to the orthosteric site of the human GLP-1 receptor. This inhibits endogenous and exogenous GLP-1 (7-36) amide-induced cAMP accumulation in target cells, such as INS-1 832/13 pancreatic β-cell lines, as demonstrated in FRET-based cAMP assays at 37°C and pH 7.4 (Chepurny et al., 2019). Unlike full-length GLP-1, the (9-36) amide fragment lacks insulinotropic activity and does not activate GLP-1R-mediated signaling. Instead, it acts as a neutral antagonist, blocking both physiological and pharmacological GLP-1 stimulation. This mechanism is distinct from other incretin antagonists, such as exendin(9–39), but both are used to parse receptor-specific effects in metabolic models (compare with FRET-based insights). This article extends prior reviews by detailing the antagonist's mechanistic selectivity and FRET assay benchmarks.

Evidence & Benchmarks

• GLP-1 (9-36) amide blocks GLP-1 (7-36) amide-induced cAMP accumulation in INS-1 832/13 pancreatic β-cells at concentrations ≥1 μM, under 5 mM glucose and standard extracellular saline conditions (Chepurny et al., 2019, DOI).
• High-throughput FRET assays confirm that GLP-1 (9-36) amide exhibits no agonist activity at the GLP-1R, ensuring specificity for antagonist studies (Chepurny et al., 2019, DOI).
• The peptide is confirmed to be >99% pure by HPLC and mass spectrometry in commercial preparations (APExBIO, product page).
• GLP-1 (9-36) amide is insoluble in water, DMSO, and ethanol, requiring specialized solvents or buffer systems for experimental use (APExBIO, product documentation).
• Storage at -20°C under desiccated conditions preserves peptide integrity for at least 12 months (APExBIO, specification sheet).
• GLP-1 (9-36) amide does not exhibit significant cross-reactivity with glucagon or GIP receptors at concentrations up to 10 μM in cellular assays (Chepurny et al., 2019, DOI).
• Prompt use after reconstitution is recommended due to rapid loss of activity in solution at room temperature (APExBIO, handling guide).

This extends the data synthesis in AvacoPanChems' analysis by specifying solubility, purity, and functional antagonism benchmarks under defined experimental conditions.

Applications, Limits & Misconceptions

GLP-1 (9-36) amide is central to studies investigating GLP-1 receptor signaling, metabolic regulation, and type 2 diabetes. Its use as a selective antagonist enables mechanistic dissection of GLP-1's role in insulin secretion, appetite control, and energy homeostasis. The peptide is also applied in models of incretin hormone crosstalk, allowing researchers to distinguish GLP-1-specific effects from those mediated by glucagon or GIP. Protocols involving GLP-1 (9-36) amide are foundational in validating new GLP-1-based therapeutics and in delineating receptor pathway contributions to glucose homeostasis (Peptide-YY.com—this article updates their workflow integration focus with new antagonist selectivity data).

However, several boundaries and misconceptions persist:

Common Pitfalls or Misconceptions

• Non-Specific Actions at Other GPCRs: At concentrations above 10 μM, GLP-1 (9-36) amide may weakly interact with non-GLP-1 GPCRs, but is generally selective at recommended experimental doses (Chepurny et al., 2019).
• Solubility Constraints: Insolubility in standard solvents can result in incomplete dosing or precipitation; always verify dissolution using proper buffer systems and gentle agitation (APExBIO).
• Instability in Solution: The peptide rapidly degrades at room temperature; avoid extended incubation after reconstitution (APExBIO).
• Not a Therapeutic Agent: GLP-1 (9-36) amide is strictly for research use and not approved for clinical or diagnostic applications (product disclaimer).
• Does Not Mimic GLP-1 Agonism: The peptide does not activate GLP-1R or stimulate insulin secretion, and should not be used as a surrogate for GLP-1 agonists in functional studies (Chepurny et al., 2019).

Workflow Integration & Parameters

For optimal experimental use, GLP-1 (9-36) amide (SKU B5404, APExBIO) is supplied as a lyophilized powder with a molecular weight of 3089.44 Da and chemical formula C₁₄₀H₂₁₄N₃₆O₄₃. Dissolve only in recommended buffers, such as 0.1% TFA in water or compatible aqueous-organic mixtures, under sterile conditions. Prepare aliquots immediately before use and maintain at 4°C or on ice during the experiment. Avoid repeated freeze-thaw cycles; store lyophilized material at -20°C in a desiccator. Use within 12 months for maximum activity. Quality control includes a Certificate of Analysis and MSDS with each lot. Purity is confirmed at ≥99% by HPLC and electrospray MS (see B5404 kit documentation).

Recommended concentrations for cell-based assays are 1–10 μM, titrated based on cell type and endpoint. Functional antagonism can be quantified using FRET-based cAMP biosensors or ELISA for downstream effectors. For detailed experimental protocols, see the manufacturer’s workflow guide and recent mechanistic reviews (Peptide-YY.com—this article clarifies antagonist dosing and QC relative to their translational focus).

Conclusion & Outlook

GLP-1 (9-36) amide is a precise and validated antagonist for human GLP-1 receptor research. Its rigorously controlled purity, specificity, and handling requirements make it indispensable for metabolic regulation, incretin hormone signaling, and type 2 diabetes research. As new peptide-based therapeutics and receptor modulators are developed, the role of GLP-1 (9-36) amide in benchmarking pathway specificity and antagonism will remain central to translational and mechanistic studies. For product details and ordering, refer to the GLP-1 (9-36) amide product page at APExBIO.